Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Teva Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Doug who wrote (233)	8/1/1998 10:02:00 AM
From: Harold Engstrom	Read Replies (1) \| Respond to of 340

It is always difficult to predict reasons for why things happen. Earnings can fluctuate for many reasons, and many of todays most successful biotech and pharmaceutical companies see large fluctuations in earnings from quarter to quarter. If you accept the consensus estimates for this year's and next year's earnings ($1.99 and $2.72), it would be hard not to imagine Teva trading significantly higher. With that kind of growth rate and those kind of earnings, one can see Teva at a PE of 30 w/o too much trouble. It still remains to be seen if Teva can execute those earnings, but if they can then this is a stock to buy and hold.